AZN reported $2.63 eps this morning (.13 beat) and beat on revenue with just past $15 billion for the quarter. More important they reiterated guidance of $80 billion for 2030. 33% higher than 2026. They also reported a positive readout on some cancer drug with $5 billion annual potential. So I’m betting we get some upgrades tomorrow with August $155 calls. I also like sector rotation. AZN has lagged the other premier pharma companies. I’m sure someone here knows a lot more about Bug Pharma t
CryptoAlerta — análise de criptomoedas e mercado em tempo real